Barclays analyst Gena Wang lowered the price target on Editas Medicine (NASDAQ: EDIT) to $5.00 (from $7.00) while maintaining a ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

Chardan Capital Markets Reiterates Buy Rating on Editas Medicine (EDIT)November 5, 2024 4:19 PM Editas Medicine (EDIT) PT Lowered to $5 at RBC CapitalNovember 4, 2024 3:25 PM Editas Medicine (EDIT) PT Lowered to $8 at Truist SecuritiesNovember 4, 2024 12:25 PM Raymond James Downgrades Editas Medicine (EDIT) to Market PerformNovember 4, 2024 12:23 PM Form SC 13G/A Editas Medicine, Inc. Filed by: VANGUARD GROUP INCNovember 4, 2024 11:57 AM Editas Medicine (EDIT) Reports In-Line Q3 EPSNovember 4, 2024 7:45 AM Form 10-Q Editas Medicine, Inc. For: Sep 30November 4, 2024 7:37 AM Form 8-K Editas Medicine, Inc. For: Nov 04November 4, 2024 7:34 AM Editas Medicine Announces Third Quarter 2024 Results and Business UpdatesNovember 4, 2024 7:30 AM